Research progress in tamoxifen in treatment of encapsulating peritoneal sclerosis

Abstract

Encapsulating peritoneal sclerosis（EPS）is a rare and serious complication in patients with long-term peritoneal dialysis and a history of recurrent and severe peritoneal dialysis-associated peritonitis（PDAP）. Early diagnosis of EPS is difficult，clinical prognosis is poor，and the fatality rate is high. The pathogenesis of EPS is still not fully understood，and ideal prevention and treatment regimens are still lacking. Tamoxifen，a selective estrogen receptor modulator，is currently used in the treatment of breast cancer，ovarian cancer and some diseases characterized by fibrotic lesions. Studies have shown that tamoxifen can also be used to treat EPS. In this article，research progress in EPS and tamoxifen in the treatment of EPS was systematically reviewed.

Keywords

• tamoxifen|encapsulating peritoneal sclerosis|selective estrogen receptor modulators|peritoneal dialysis|therapy